People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Participants were randomly assigned to once-weekly semaglutide 7.2 mg, once-weekly semaglutide 2.4 mg (Wegovy ... More detailed results from the STEP UP trial are expected to be presented at ...

In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically significant ... which resulted in losses of 17.5% and 2.4%, respectively. In addition, 33.2% of subjects receiving the ...

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy ... Step Up trial was conducted to test the efficacy of the higher dose, as the current highest dose available is 2.4 ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy ... 1b/2a clinical trial for the ...

Semaglutide 2.4 mg is marketed under the brand name Wegovy. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo ...

STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo ... already established with Wegovy ®, including ...

Citing topline data from its STEP-UP Phase 3b study, the Danish drugmaker said that while patients on regular Wegovy at 2. ... placebo experienced 2.4% weight loss. The trial involving more than ...